Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + bacillus Calmette-Guérin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravesical, Intravenous
01
Overview
Imfinzi + bacillus Calmette-Guérin is an immunotherapy combination regimen consisting of durvalumab (Imfinzi), a human monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1), and bacillus Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis. Developed by AstraZeneca, this combination is approved in the United States for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval was supported by results from the Phase III POTOMAC trial, which demonstrated that adding one year of durvalumab to standard BCG induction and maintenance therapy significantly reduced the risk of high-risk disease recurrence, progression, or death by 32% compared to BCG alone.
- Other names
- durvalumab + bacillus Calmette-Guerindurvalumab + BCGImfinzi + bacillus Calmette-GuerinImfinzi + bacillus Calmette-GuérinImfinzi + BCG
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on durvalumab + bacillus Calmette-Guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + bacillus Calmette-Guérin.